Letošní EAHP Academy Seminar se konal 12.-14.9. 2013 v portugalském Lisabonu. Tématem bylo "Pharmacoeconomics - tools, strategies and beyond". Za Českou replubliku se zúčastnili Hojný, Horák a Šimíček. Seminář nebyl určen striktně pouze pro farmaceuty z nových členských států EU a  EAHP (zemí jižních a východních :-)),  ale účastnili se i kolegové ze západoevropských států, Německa, Irska, Beneluxu apod.

V současné nemocniční lékárně v moderním pojetí se stále častěji setkáváme s potřebou znalostí  základů farmakoekonomiky. Tyto teoretické znalosti a praktické dovednosti lze využít s cílem šetřit rozpočet nemocnice. Jsme zvyklí řešit jednoduché úkoly, jako je cena léku od distributorů, náklady na přípravu a kontrolu kvality v lékárně, náklady na administrativu, personál, vybavení apod, ale složitější farmakoekonomické analýzy běžně neprovádíme. Seminář měl přinést účastníkům informace z různých oblastí farmakoekonomiky.

Velký prostor byl (jako obvykle) věnován aktivní diskusi účastníků, ke každému semináři se konal workshop s několika úkoly zakončený prezentací výsledků diskuse ostatním skupinám.

V článku níže jsou abstrakta jednotlivých seminářů spolu s odkazem na plné verze prezentací. Prezentace (Seminar III) není na přání přednášejícího zveřejněna, k dispozici u autora příspěvku

Seminar I:  Jean-Christophe Devaud - General, Public Health and Pharmacoeconomics

Abstract

Pharmacoeconomics as one of the tasks stipulated in a hospital pharmacist’s employment contract is to satisfy particularly the financial interests of employers, governments, administrations and taxpayers. However, physicians and patients are further players in public health who have an interest of their own in the outcome of a case. The hospital pharmacist may be in a conflict of interest as he has to integrate clinical, financial and quality of life requests.
Incompatible interests of key-players are the reason why macroeconomic approaches generally fail in public health. The market as coordinating mechanism, true providers, consumers, offer and demand do not exist accordingly. There is much regulation and many ideological doctrines. Advice on how to obtain a favourable cost-benefit ratio is as broad as interests.

Teaching goals

Learning objectives

Seminar II: Olivia Wu - From policy (-> pharmacoeconomics) to science (-> pharmacoeconomics analysis and research)

Abstract

Pharmacoeconomics is a scientific discipline that evaluates pharmaceutical interventions, taking into account both costs and the value of health benefits.  The methodologies used in pharmacoeconomic evaluations may be varied and often complex.  The most common approaches include: cost-effectiveness analysis, cost-utility analysis, cost-consequence analysis, cost-minimisation analysis and cost-benefit analysis.  Increasingly, policy makers are requiring pharmacoeconomic evidence to support their decisions on the adoption of pharmaceutical interventions within a health technology assessment framework; pharmacoeconomic evaluations are important tools to aid these decisions on the adoption of new pharmaceutical and non-pharmaceutical interventions.

Seminar III:  Stefan Vegter - Discrepancy between clinical decisions and economic factors

Abstract (prezentace na vyžádání u autora příspěvku)

This seminar will cover the availability of medicines and the reimbursement rules, i.e. marketed drugs are principally available, but are they reimbursed in every case? An ethical and (logical “and”) financial approach on whether all patients get equal therapies and care will be developed. If not all medicines are readily available to all patients the outcome may suffer. Very expensive drugs such as cytotoxics or biotechnologically produced drugs are restrictedly used. Less available may be as well drugs used in clinical trials, parallel trials, compassionate cases, orphan drugs, and/or preparations.

Teaching goals

Learning objectives

Delegates
• conciliate interests of therapists, administrators, taxpayers, and patients involved in providing access to therapies and reimbursement decisions
• possess tools to resolve discrepancies between clinical decisions and economic factors.

Seminar IV:  Francisco Ramos- Financing models and the budgeting process

Abstract

In recent years, many governments and authorities have passed from fixed to global budgets allocated to public health hospitals, which have to plan and decide on financial resources on their own. A common way is to pass the token to the departments and clinics, which play the same game again. A hospital pharmacy is at the final position, gets its budget and has to periodically pass controlling. However, the use of medicines depends on the patient-mix which cannot be precisely foreseen. The hospital pharmacist may be in a conflict of interest if budgets may get out of control while he has to defend the patients’ interests. As to close the circle to Seminar I, an added value of patients recovered and reintegrated in the production process is booked in another sector outside public health. The public health sector may have no choice than to accept its role as a cost producer.

Teaching goals

Learning objectives

Komentáře

B

i

u

Quote

Code

List

List item

URL

Jméno *
Mail
Opište kód   
ChronoComments by Joomla Professional Solutions

Přidat komentář